The number of NG2 positive tumour microvessels was also significantly reduced by the NG2 shRNAs compared to control shRNA treated tumours (Fig. 3F1-2 and 3G right panel, p = 0.0025 t-test). The gene discussed is CSPG4; the disease is neoplasm.